@article{TCR8832,
author = {Malte W. Vetterlein and Quoc-Dien Trinh and Felix K. H. Chun},
title = {Novel non-invasive urine-based gene expression assay discriminates between low- and high-risk prostate cancer before biopsy},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 2},
year = {2016},
keywords = {},
abstract = {Prostate-specific antigen (PSA)-based screening programs are controversial, and influential guideline panels have recommended against PSA screening in all men. A main limitation of PSA-based blood tests is the lack of a valid threshold to distinguish between a malignant and a benign condition. In addition, PSA screening generally fails to differentiate between low- and high-grade prostate cancer and thus, is not able to prevent patients from unnecessary biopsies. Alternative, urine-based tests have recently been developed and provide promising predictive accuracy regarding the aggressiveness of the disease. Two markers—prostate cancer antigen 3 (PCA3) and an androgen-related fusion protein (TMPRSS2-ERG)—were combined into a urine test several years ago. This Mi-Prostate Score (MiPS) significantly outperformed both PCA3 + PSA and PSA alone for the prediction of high-grade prostate cancer before biopsy. To date, these tests need pre-collection digital rectal examination to improve the predictive ability. Against this backdrop, a recent study presented a novel urine-based assay, using an exosome-derived gene expression signature. In a validation cohort of 519 patients, the area under receiver operating characteristic curve (AUC) showed superior predictive ability in the discrimination of Gleason scores ≥7 and },
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/8832}
}